Últimas noticias sobre Bank CIMB Niaga (OTC:PTNAF) Bolsa

PT Bank CIMB Niaga Tbk operates in the commercial banking sector. Its principal activities include accepting funds from the public in the form of deposits, namely current accounts, time deposits, certificates of deposits, and saving accounts; providing loans, safe deposit boxes, and online banking facilities; performing custodian and treasury activities; offering credit cards, factoring, and trust services; and others. The company's reportable segments are Corporate, Business, Retail, Treasury, Sharia, Others, and Subsidiaries. Maximum revenue is generated from its Retail segment, which focuses on providing products and services to individual customers. It includes products such as loans, deposits, and other transactions, and balances with retail customers.

PT Bank CIMB Niaga Tbk

News

Management

NPCE

NeuroPace Appoints Patrick F. Williams As CFO, Effective June 20, 2025

Based on Mirion's proTK&#x2122; Product Line, the Newly Designed Solution Aims to Reduce Burden and Enhance Performance in Nuclear Power Plants.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.mirion.com%2Fabout%2Fmirion-technologies&amp;esheet=54281210&amp;newsitemid=20250624849892&amp;lan=en-US&amp;anchor=Mirion+Technologies&amp;index=1&amp;md5=f0e0e1dcb6123518d9c3f989296979f8">Mirion Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>), a leading provider of advanced radiation safety solutions, and Westinghouse Electric Company LLC, a leading supplier of nuclear plant instrumentation and control systems, have announced a strategic partnership to provide digital Ex-core Nuclear Instrumentation Systems (NIS) based on the high-performing Mirion proTK product line. This collaboration aims to alleviate operator and maintenance burdens, enhance performance, and ensure sustained operation success. This digital NIS upgrade solution is offered exclusively through Westinghouse for both Westinghouse and Combustion Engineering designed PWRs worldwide.
This initiative leverages Mirion's proTK product line to upgrade existing analog neutron flux monitoring drawers, which were originally designed in the 1960s, to a state-of-the-art digital system. The Mirion proTK product line represents an advanced and reliable Ex-core neutron flux measurement solution to replace the outdated equipment that can be costly and labor-intensive to maintain. Additionally, the Westinghouse and Mirion collaboration provides a drop-in replacement for legacy systems, minimizing disruptions to operations and training. With over 400 drawers implemented globally, reflecting more than 4000 operating years, Mirion's proTK product line has a proven track record for reliability and performance in nuclear facilities of any size and complexity.

Mirion And Westinghouse Partner To Digitally Upgrade Nuclear Instrumentation Systems With proTK Technology

Guidance

FedEx Sees Q1 EPS $3.40-$4.00 After Excluding Costs Relate To Business Optimization Initiatives And Planned Spinoff Of FedEx Freight.

AVAV

AeroVironment Sees FY2026 Adj EPS $2.80-$3.00 vs $3.72 Est; Sees Sales $1.900B-$2.000B vs $1.98B Est

Teck Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>) has outperformed the market over the past 5 years by 16.27% on an annualized basis producing an average annual return of 31.09%. Currently, Teck Resources has a market capitalization of $19.13 billion. 
Buying $100 In TECK: If an investor had bought $100 of TECK stock 5 years ago, it would be worth $389.93 today based on a price of $38.41 for TECK at the time of writing.
<h3>Teck Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750795424_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TECK

Here's How Much $100 Invested In Teck Resources 5 Years Ago Would Be Worth Today

FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) reported quarterly earnings of $6.07 per share which beat the analyst consensus estimate of $5.87 by 3.46 percent. This is a 12.2 percent increase over earnings of $5.41 per share from the same period last year. The company reported quarterly sales of $22.200 billion which beat the analyst consensus estimate of $21.837 billion by 1.66 percent. This is a 0.45 percent increase over sales of $22.100 billion the same period last year.

Earnings

Earnings Beats

FedEx Q4 Adj. EPS $6.07 Beats $5.87 Estimate, Sales $22.200B Beat $21.837B Estimate

&nbsp;PDUFA action date set for October 25, 2025 –
– sNDA being reviewed under FDA's RTOR program –
– Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia –
&nbsp;Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj&#xAE; (revumenib) for the treatment of relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML). The sNDA is being reviewed under the&nbsp;FDA's&nbsp;Real-Time Oncology Review (RTOR) program and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 25, 2025. RTOR allows for a more efficient review and close engagement between the sponsor and the FDA throughout the submission process.
"We are pleased that the FDA has granted Priority Review to our sNDA in R/R mNPM1 AML, a filing which builds on the initial approval of Revuforj for R/R acute leukemia with a KMT2A translocation in 2024," said&nbsp;Michael A. Metzger, Chief Executive Officer. "Syndax is uniquely positioned to continue leading this exciting new therapeutic class with a first- and best-in-class menin inhibitor supported by compelling pivotal data across the broadest population of patients and a strong foundation already established among clinicians, payers, and other key stakeholders."
Revuforj is an oral, first-in-class menin inhibitor that was FDA approved in 2024 for the treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. The sNDA, if approved, would expand the indication for Revuforj to include patients with R/R AML who have an NPM1 mutation, the most common genetic alteration in AML. The sNDA is supported by positive pivotal data from the AUGMENT-101 trial of revumenib in patients with R/R mNPM1 AML. Results from this population were <a href="https://www.globenewswire.com/Tracker?data=D7tUD7eVEn5JLkYOeQrU-BOayua6_ug1l4j6NOo0-fsplgnyW0LzHzB2o-32jI_VSk8eFJmv88J4bf1HnNFCyVLz_0_-R6yayguL0wrTyr7wfRZYyTtvSzo7mI2I37ywk7WY9YnKd3-HmqTtzte-HaxTNiDb4ImpyOYm31zcONG2O2Q4jDoF2qZ_C9wIdvwdQ6MwXMm3fyPp5ga60JtKX8CxOqH0rZ_8l-IsJuiVOUE=">published</a> in the journal Blood in May 2025 and <a href="https://www.globenewswire.com/Tracker?data=cqLThb98RkuYnOJo1UJRMFAIZM_9e9hN8tvaO3evDJPQuKGGfjpoFvkBIb0HowonFoUy0y0pBhHFm6-RUzSPJeXnMh6XLsw2zAze4KKDjXn3CzhIKjg2W_CtWQeXMcuN0oRVGhRLkh6vb4QB4J8Aa0NLC_f_02I2vHQchSYI9_8vjLYhmigJMtFjR-VFRvvF">presented</a> at the European Hematology Association (EHA) Annual Congress Meeting in June 2025.
About Mutant NPM1 (mNPM1) Acute Myeloid Leukemia (AML)
Mutations in the NPM1 gene are the most common genetic alteration observed in adults with AML, occurring in approximately 30% of cases. Mutations in this gene play a critical role in the development of mutant NPM1 (mNPM1) AML, an aggressive blood cancer associated with high rates of relapse. Patients with relapsed or refractory mNPM1 AML have a poor prognosis and critical unmet need. Similar to KMT2A-rearranged acute leukemia, mNPM1 AML is highly dependent on the menin-KMT2A interaction and disruption of this interaction has been shown to lead to downregulation of certain leukemogenic genes. mNPM1 AML is routinely diagnosed through currently available screening techniques. There are currently no approved therapies that selectively target the underlying disease mechanisms driving mNPM1 AML.

Biotech

General

SNDX

Syndax Pharmaceuticals Announces That The FDA Has Granted Priority Review For Its Supplemental New Drug Application For Revuforj In Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

VSTM

Verastem Oncology Doses First Patient With VS-7375 In Phase 1/2a Trial

AeroVironment Q4 Adj. EPS $1.61 Beats $1.42 Estimate, Sales $275.05M Beat $242.69M Estimate

–&nbsp;PDUFA action date set for October 25, 2025 –
– sNDA being reviewed under FDA's RTOR program –
– Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia –
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj&#xAE; (revumenib) for the treatment of relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML). The sNDA is being reviewed under the&nbsp;FDA's&nbsp;Real-Time Oncology Review (RTOR) program and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 25, 2025. RTOR allows for a more efficient review and close engagement between the sponsor and the FDA throughout the submission process.

Syndax's Revumenib Granted FDA Priority Review Under RTOR Program; PDUFA Date Set For October 25, 2025

Graphjet Technology Receives Nasdaq Noncompliance Letter

Forte Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock plus the shares of common stock underlying the pre-funded warrants sold in the offering. All of the shares of common stock and pre-funded warrants are being offered by Forte. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Forte intends to use the net proceeds of the offering for working capital and other general corporate purposes, which includes funding clinical and preclinical development of its product candidate and other research activities.
TD Cowen, Evercore ISI, Guggenheim Securities and Chardan are acting as joint book-running managers for the offering. Lucid Capital Markets is acting as co-manager for the offering.

Offerings

FBRX

Forte Biosciences Announces Proposed Public Offering; No Size Or Amount Disclosed

In the current market session, First Financial Bancorp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFBC#NASDAQ">FFBC</a>) share price is at $24.33, after a 2.49% increase. Moreover, over the past month, the stock decreased by 0.73%, but in the past year, went up by 12.74%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1750795262_0.png" alt="Past Year Chart" />

<h3>How Does First Financial Bancorp P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
First Financial Bancorp has a lower P/E than the aggregate P/E of 15.43 of the Banks industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750795262_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

FFBC

Price Over Earnings Overview: First Financial Bancorp

Airline stocks such as Delta Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NASDAQ">DAL</a>) and United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) are trading higher Tuesday following a sharp decline in oil prices and growing hopes for a<a href="https://www.benzinga.com/news/events/25/06/46068524/israel-says-iran-broke-trump-ceasefire-orders-high-intensity-strikes-on-tehran"> ceasefire between Iran and Israel.</a>
What To Know: The gains come as Brent crude and other oil benchmarks fell sharply. 
The United States Brent Oil Fund (BNO) dropped over 5%; the United States Oil Fund (USO) dropped a similar amount. The selloff in energy markets was driven by President Donald Trump's announcement of a tentative ceasefire between Israel and Iran. If the truce holds, it could reduce the risk of further escalation in the oil-rich Middle East region.
Iran's foreign ministry disputed the existence of a formal agreement. Yet, it also indicated a willingness to halt operations if Israel stops its attacks. Despite the uncertainty, markets are reacting to the possibility that immediate conflict may subside. A resolution could stabilize oil flow through the Strait of Hormuz, a key passage for global crude shipments.
The resulting drop in jet fuel and broader oil prices is potentially seen as a positive development for the airline sector, which is highly sensitive to fuel costs. Additionally, the reduced geopolitical risk may ease concerns around travel demand in international markets. However, with Israel accusing Iran of violating the ceasefire on Tuesday, the situation remains fluid and volatile.
Price Action: Delta shares were up 2.59% at $49.50 and United Arline shares were 2.72% at $79.06 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46067898/trumps-crypto-ventures-have-been-lucrative-but-adam-schiff-says-he-is-bringing-in-a-law-to-end-corruption-in-plain-sight">Trump&#8217;s Crypto Ventures Have Been &#8216;Lucrative,&#8217; But Adam Schiff Says He Is Bringing In A Law To End &#8216;Corruption In Plain Sight&#8217;</a></li>
</ul>
Image Via Shutterstock.

Movers

What's Going On With Airline Stocks Today?

8 analysts have expressed a variety of opinions on Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $47.38, with a high estimate of $60.00 and a low estimate of $41.00. A decline of 8.44% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1750795258_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Fluor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$49.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Fluor. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fluor compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Fluor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Fluor's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FLR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fluor analyst ratings.</a>
<h2>Unveiling the Story Behind Fluor</h2>
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. The firm serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.
<h3>Financial Milestones: Fluor's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Fluor displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 6.64%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Fluor's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -6.05%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Fluor's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.39%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Fluor's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.74%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.3.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Fluor In The Eyes Of 8 Experts

Sadot Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) ("Sadot Group", "Sadot" or the "Company"), an emerging player in the global Agri-food supply chain, is pleased to announce that Claudio Torres has been appointed as Chairman of the Board, effective June 18, 2025. Mr. Torres joined Sadot's Board of Directors on February 20, 2025, and recently served as Vice Chairman. He currently is, and will remain, a member of the compensation committee. Mr. Torres brings over 30 years of leadership across the global agriculture, food production, and supply chain sectors-including executive roles at industry powerhouses such as Monsanto, Syngenta, and Advanta Seeds.
Mr. Torres will be joining Mr. Chagay Ravid, who was recently named CEO of Sadot Group, in leading Sadot through its next growth cycle.

SDOT

Sadot Group Announces Claudio Torres Has Been Appointed As Chairman Of The Board, Effective June 18, 2025

Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $123.12, a high estimate of $140.00, and a low estimate of $100.00. Highlighting a 4.13% decrease, the current average has fallen from the previous average price target of $128.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1750795251_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Science Applications Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Siegmann</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>David Strauss</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$137.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Gavin Parsons</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$111.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Sheila Kahyaoglu</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Seth Seifman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$148.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Science Applications Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Science Applications Intl compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Science Applications Intl's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Science Applications Intl's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SAIC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Science Applications Intl analyst ratings.</a>
<h2>Get to Know Science Applications Intl Better</h2>
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the Department of Defence (DoD) and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.
<h3>Unraveling the Financial Story of Science Applications Intl</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, Science Applications Intl showcased positive performance, achieving a revenue growth rate of 1.62% as of 30 April, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Science Applications Intl's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 3.62%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Science Applications Intl's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.41%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Science Applications Intl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.3%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Science Applications Intl's debt-to-equity ratio is below the industry average. With a ratio of 1.62, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAIC

Assessing Science Applications Intl: Insights From 8 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $760.0, a high estimate of $921.00, and a low estimate of $485.00. Highlighting a 2.81% decrease, the current average has fallen from the previous average price target of $782.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1750795243_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive United Rentals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$810.00</td>
<td>$740.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$850.00</td>
<td>$770.00</td>
</tr>
<tr>
<td>Ken Newman</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$865.00</td>
<td>-</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$920.00</td>
<td>$780.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$921.00</td>
<td>$974.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$780.00</td>
<td>$485.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$786.00</td>
<td>$732.00</td>
</tr>
<tr>
<td>Mircea Dobre</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$571.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$750.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$650.00</td>
<td>$720.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$732.00</td>
<td>$956.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$485.00</td>
<td>$910.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to United Rentals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of United Rentals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Rentals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of United Rentals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/URI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on United Rentals analyst ratings.</a>
<h2>Delving into United Rentals's Background</h2>
United Rentals is the world's largest equipment rental company. It principally operates in the United States and Canada, where it commands approximately 15% share in a highly fragmented market. It serves three end markets: general industrial, commercial construction, and residential construction. Like its peers, United Rentals historically has provided its customers with equipment that was intermittently used, such as aerial equipment and portable generators. As the company has grown organically and through hundreds of acquisitions since it went public in 1997, its catalog (fleet size of $21 billion) now includes a range of specialty equipment and other items that can be rented for indefinite periods. 2024 revenue totaled $15.3 billion.
<h3>Unraveling the Financial Story of United Rentals</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: United Rentals displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 6.71%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.93%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 5.95%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): United Rentals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.84%, the company showcases efficient use of assets and strong financial health.
Debt Management: United Rentals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.59.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: United Rentals In The Eyes Of 12 Experts

In the preceding three months, 23 analysts have released ratings for Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">13</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $111.7, a high estimate of $135.00, and a low estimate of $85.00. Witnessing a positive shift, the current average has risen by 18.83% from the previous average price target of $94.00.
<img src="https://www.benzinga.com/files/images/story/2025/1750795235_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Dollar General. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$116.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$117.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$112.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Bobby Griffin</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$112.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$128.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$119.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$93.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$101.00</td>
<td>$69.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dollar General. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dollar General compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Dollar General's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dollar General's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dollar General analyst ratings.</a>
<h2>All You Need to Know About Dollar General</h2>
With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged food, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.
<h3>Dollar General's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Dollar General's revenue growth over a period of 3M has been noteworthy. As of 30 April, 2025, the company achieved a revenue growth rate of approximately 5.26%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Dollar General's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 3.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dollar General's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 5.19%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.26%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Dollar General's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.21, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Dollar General Stock

Somnigroup International's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) short percent of float has fallen 4.8% since its last report. The company recently reported that it has 17.63 million shares sold short, which is 8.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Somnigroup International Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750795230_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Somnigroup International has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Somnigroup International's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Somnigroup International's peer group average for short interest as a percentage of float is 5.75%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Comments

Bank CIMB Niaga

Noticias

Últimas noticias sobre Bank CIMB Niaga (OTC:PTNAF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL